Initial Management of Atrial Fibrillation with Rapid Ventricular Response

Assessment and Management

The American Heart Association recommends determining hemodynamic stability in patients with AF and RVR, with signs of instability including hypotension, ongoing ischemia, altered mental status, and shock 1, 2, 3, 4, 5
The American College of Cardiology suggests that patients with hemodynamic compromise, ongoing ischemia, or inadequate rate control should undergo immediate direct-current cardioversion 1, 4
Anticoagulation should be initiated concurrently if AF duration is >48 hours or unknown, according to the European Heart Journal 2, 4
The American Heart Association recommends against delaying cardioversion for anticoagulation in truly unstable patients 1, 6

For patients with preserved ejection fraction (LVEF >40%), the European Heart Journal recommends first-line options including intravenous beta-blockers (e.g., metoprolol) and intravenous non-dihydropyridine calcium channel blockers (e.g., diltiazem, verapamil) 5, 7
For patients with reduced ejection fraction (LVEF ≤40%), the American Heart Association suggests first-line options including intravenous beta-blockers (metoprolol preferred) and intravenous digoxin (particularly if severe LV dysfunction) 3, 5
The American College of Cardiology recommends avoiding calcium channel blockers in decompensated heart failure 3

For patients with AF and acute coronary syndrome, the American Heart Association recommends intravenous beta-blockers if no contraindications exist, and considers amiodarone or digoxin if severe LV dysfunction or hemodynamic instability is present 1, 8
For patients with AF and COPD, the European Heart Journal recommends non-dihydropyridine calcium channel antagonist and avoiding beta-blockers if active bronchospasm is present 1, 8
For patients with AF and Wolff-Parkinson-White syndrome, the American Heart Association recommends avoiding AV nodal blocking agents and using procainamide or ibutilide if hemodynamically stable, and immediate cardioversion if unstable 1, 8

The European Heart Journal suggests considering pharmacological cardioversion for recent-onset AF (<48 hours) with options including intravenous flecainide or propafenone, intravenous vernakalant, and intravenous amiodarone 2, 4

The American Heart Association recommends initiating anticoagulation based on CHA₂DS₂-VASc score, with anticoagulation recommended for patients with CHA₂DS₂-VASc ≥2 1, 8
The European Heart Journal prefers direct oral anticoagulants (DOACs) over vitamin K antagonists in eligible patients 2, 4
For patients undergoing cardioversion, the European Heart Journal recommends providing 3 weeks of therapeutic anticoagulation before cardioversion or performing transesophageal echocardiography, and continuing anticoagulation for at least 4 weeks after cardioversion 2, 4